<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580878</url>
  </required_header>
  <id_info>
    <org_study_id>BTNF 1104</org_study_id>
    <nct_id>NCT01580878</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety &amp; Bioequivalence of a Generic Butenafine Cream &amp; Lotrimin Ultra® &amp; Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the comparability of the safety and&#xD;
      efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra®&#xD;
      (the reference listed drug) in subjects with interdigital tinea pedis. It will also be&#xD;
      determined whether the efficacy of each of the two active treatments is superior to that of&#xD;
      the vehicle cream (placebo).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Cure</measure>
    <time_frame>42 days</time_frame>
    <description>Subjects with both clinical cure and mycologic cure are considered therapeutic cures.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">707</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Butenafine Hydrochloride Cream, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrimin Ultra®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butenafine Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Hydrochloride Cream, 1%</intervention_name>
    <description>Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days</description>
    <arm_group_label>Butenafine Hydrochloride Cream, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotrimin Ultra®</intervention_name>
    <description>Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.</description>
    <arm_group_label>Lotrimin Ultra®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Vehicle</intervention_name>
    <description>Butenafine Vehicle applied twice daily for 7 consecutive days.</description>
    <arm_group_label>Butenafine Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing &amp; able to provide &amp; understand written informed consent&#xD;
&#xD;
          -  Healthy male or non-pregnant, non-lactating female at least 18 years of age and older&#xD;
&#xD;
          -  Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or&#xD;
             that is predominantly interdigital but may extend to other areas&#xD;
&#xD;
          -  Tinea pedis provisionally confirmed at baseline by positive potassium hydroxide&#xD;
             (KOH)wet mount preparation showing segmented fungal hyphae&#xD;
&#xD;
          -  Has sum of the clinical signs and symptoms scores of the target lesion of at least 4,&#xD;
             including a minimum score of 2 for erythema &amp; a minimum score of 2 for scaling or&#xD;
             pruritus&#xD;
&#xD;
          -  Currently in general good health with no clinically significant disease&#xD;
&#xD;
          -  Willing and able to understand and comply with study requirements&#xD;
&#xD;
          -  Women of childbearing potential must have a negative urine pregnancy test and be&#xD;
             willing to use an acceptable form of birth control during study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, planning a pregnancy, or do not agree to use&#xD;
             an acceptable form of birth control during the study&#xD;
&#xD;
          -  Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface&#xD;
&#xD;
          -  Presence of any other infection of the foot or other disease that might confound&#xD;
             treatment evaluation&#xD;
&#xD;
          -  History of dermatophyte infections unresponsive to antifungal drugs&#xD;
&#xD;
          -  Known hypersensitivity to Butenafine Hydrochloride or any component of the study&#xD;
             medications&#xD;
&#xD;
          -  Use of antipruritics, topical systemic corticosteroid, antibiotic or antifungal&#xD;
             therapy, oral terbinafine or itraconazole, or immunosuppressive medication or&#xD;
             radiation therapy more recently than indicated washout period&#xD;
&#xD;
          -  Current oral, vaginal, or mucocutaneous candidiasis&#xD;
&#xD;
          -  Current bacterial skin infection, secondary cellulitis, lymphangitis, or pyoderma&#xD;
&#xD;
          -  Presence of current conditions that require systemic antimicrobial or antifungal&#xD;
             therapy&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, peripheral vascular disease, chronic venous stasis, or&#xD;
             other significant condition&#xD;
&#xD;
          -  Current severe onychomycosis&#xD;
&#xD;
          -  Any clinically significant condition or situation, other than condition being studied,&#xD;
             that would interfere with the study evaluations or participation&#xD;
&#xD;
          -  Use of any investigational drugs or device within 30 days of signing Informed Consent&#xD;
             Form (ICF)&#xD;
&#xD;
          -  Current participation in any other clinical study&#xD;
&#xD;
          -  Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would&#xD;
             compromise compliance&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Subjects with past history of tinea pedis with lack of response to antifungal therapy&#xD;
&#xD;
          -  Subjects who in Investigator's opinion would be non-compliant&#xD;
&#xD;
          -  Employees or direct relatives of an employee of the study center or Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Symbio CRO</last_name>
    <role>Study Chair</role>
    <affiliation>http://symbioresearch.com/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Butenafine Hydrochloride Cream, 1%</keyword>
  <keyword>Lotrimin Ultra® Cream, 1%</keyword>
  <keyword>Interdigital Tinea Pedis</keyword>
  <keyword>Safety and Bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butenafine</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

